GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Beta

Regenicin (Regenicin) Beta : 3.71 (As of May. 11, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Regenicin Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-11), Regenicin's Beta is 3.71.


Regenicin Beta Historical Data

The historical data trend for Regenicin's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Beta Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 2.86 0.42 1.05 -3.85

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -3.49 -3.85 -4.40 -3.96

Competitive Comparison of Regenicin's Beta

For the Biotechnology subindustry, Regenicin's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regenicin's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's Beta distribution charts can be found below:

* The bar in red indicates where Regenicin's Beta falls into.



Regenicin Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Regenicin  (OTCPK:RGIN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Regenicin Beta Related Terms

Thank you for viewing the detailed overview of Regenicin's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenicin (Regenicin) Business Description

Traded in Other Exchanges
N/A
Address
10 High Court, Little Falls, NJ, USA, 07424
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines